Trial Profile
Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary) ; Amlodipine; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms OLMETREAT
- Sponsors Daiichi Pharmaceutical; Sankyo
- 09 Nov 2010 Additional trial identifier EudraCT2005-004659-36 identified as reported by ClinicalTrials.gov.
- 02 May 2008 The expected completion date for this trial is now 1 Apr 2008.
- 28 Apr 2008 Status changed from recruiting to completed, reported by ClinicalTrials.gov.